Biological role and therapeutic potential of phytoflavonoids and vitamin D in the treatment of patients with uterine myoma, as well as other promising pharmacological directions

Close metadata

Recommended articles:

Predicting the risk of decreased ovarian reserve after surgical treatment of patients with deep infiltrative endometriosis using artificial intelligence. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):92-102

Controversial issues of adjuvant therapy after myomectomy. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):101-107

Platelet apoptosis markers under anticoagulation for COVID-19 infection. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(2):194-203

Experimental evaluation of the efficacy of tissue-engineered constructs in the treatment of limbal stem cell deficiency. Russian Annals of Ophthalmology. 2024;(2-2):80-89

Pathogenetic basis of optic nerve atrophy in methanol poisoning. Russian Annals of Ophthalmology. 2024;(2):91-96

Benign breast diseases in the focus of proliferative pathology of the reproductive system. Russian Journal of Human Reproduction. 2024;(3):33-42

A clinical case of parasitic fibroids on the mesentery of the sigmoid colon. Russian Journal of Human Reproduction. 2024;(3):105-110

Tolerability of multiphasic and monophasic combined hormonal contraceptives patients with uterine fibroids. Russian Journal of Human Reproduction. 2024;(4):78-89

Heterogeneity of the molecular phenotype with uterine fibroids. Message I. Russian Journal of Human Reproduction. 2024;(4):121-130

Assessment of histological changes in the lungs and Bax and Bcl-2 expression in bronchial epithelium, alveolar type 1 cells and neutrophils of rats in poisoning with baclofen. Forensic Medical Expertise. 2024;(5):36-41

The review of the results of researches made in recent years presents new approaches to treating patients with uterine myoma. Numerous studies confirm that there is a clear pathophysiological basis for the use of phytoflavonoids to treat uterine myoma, which is extremely promising. Scientists have shown a clear relationship between the lower plasma level of vitamin D and the higher risk for uterine leiomyoma, as well as its protective role in the development of this disease. In view of the enormous importance of fibrogenesis in the pathophysiology of uterine leiomyoma, there is a continuing search for an effective antifibrotic medication for additional pathogenetic therapy. Pharmacological studies aimed to design thermosensitive nanomaterials (nanoparticles) as a depot for various drugs are promising. The accurate, controlled administration of the drug into the lesion area, including in uterine myoma, will provide its long-term delay and prevent premature inactivation, which will reduce the frequency of drug administration. The new approaches to pharmacotherapy for patients with uterine myoma can substantially enhance the efficiency of treatment and minimize the number of adverse effects.

Keywords:

uterine myoma

phytoflavonoids

curcumin

calcitriol

apoptosis

fibrogenesis

collagen

nanoparticles

Authors:

Buianova S.N.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Shchukina N.A.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Babunashvili E.L.

Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia

List of references:

Dixon RA, Ferreira D. Molecules of interest: Genistein. Phytochemistry. 2002;60:3:205-211. https://doi.org/10.1016/S0031-9422(02)00116-4
Shushan A, Ben-Bassat H, Mishani E, Laufer N, Klein BY, Rojansky N. Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertility and Sterility. 2007;87:1:127-135. https://doi.org/10.1016/j.fertnstert.2006.05.056
Miyake A, Takeda T, Isobe A, Wakabayashi A, Nishimoto F, Morishige KI, Kimura T. Repressive effect of the phytoestrogen genistein on estradiol-induced uterine leiomyoma cell proliferation. Gynecological Endocrinology. 2009;25:6:403-409. https://doi.org/10.1080/09513590902730804
Di X, Andrews DM, Tucker CJ, Yu L, Moore AB, Zheng X, Dixon D. A high concentration of genistein down-regulates activin A, Smad3 and other TGF-β pathway genes in human uterine leiomyoma cells. Experimental and Molecular Medicine. 2012;44:4:281-292. https://doi.org/10.3858/emm.2012.44.4.024
Castro L, Gao X, Moore AB, Yu L, Di X, Kissling GE, Dixon D. High concentration of genistein Induces cell death in human uterine leiomyoma cells by autophagy. Expert Opin Environ Biol. 2016; 5:Suppl 1. https://doi.org/10.4172/2325-9655.S1-003
Nagle DG, Ferreira D, Zhou YD. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry. 2006;67:17: 1849-1855. https://doi.org/10.1016/j.phytochem.2006.06.020
Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Sharan C, Rajaratnam V, Khurana A, Al-Hendy A. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. American Journal Obstet Gynecol. 2010;202:3:289.e1-289.e9. https://doi.org/10.1016/j.ajog.2009.10.885
Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol-epigallocatechin-3-gallate. Cancer Research. 2006;5:2500-2505. https://doi.org/10.1158/0008-5472.CAN-05-3636
Roshdy E, Rajaratnam V, Maitra S, Sabry M, Allah AS, Al-Handy A. Treatment of symptomatic uterine fibroids with green tea extract: A pilot randomized controlled clinical study. Int J Womens Health. 2013;5:1:477-486. https://doi.org/10.2147/IJWH.S41021
Ammon HP, Wahl MA. Pharmacology of curcuma longa. Planta Med. 1991l57:1:1-7. https://doi.org/10.1055/s-2006-960004
Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res. 2003;23:1: 363-398.
Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacology. 2005;70:5:700-713. https://doi.org/10.1016/j.bcp.2005.04.043
Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. Advances in Experimental Medicine and Biology. 2007;595:127-148. https://doi.org/10.1007/978-0-387-46401-5_4
Malik M, Mendoza M, Payson M, Catherino WH. Curcumin, a nutritional supplement with antineoplastic activity, enhances leiomyoma cell apoptosis and decreases fibronectin expression. Fertil Steril. 2009;91:5 Suppl:2177-2184. https://doi.org/10.1016/j.fertnstert.2008.03.045
Tsuiji K, Takeda T, Li B, Wakabayashi A, Kondo A, Kimura T, Yaegashi N. Inhibitory effect of curcumin on uterine leiomyoma cell proliferation. Gynecol Endocrinol. 2011;27:7:512-517. https://doi.org/10.3109/09513590.2010.507287
Shanle EK, Xu W. Endocrine disrupting chemicals targeting estrogen receptor signaling: Identification and mechanisms of action. Chemical Research in Toxicology. 2011;24:1: 6-19. https://doi.org/10.1021/tx100231n
Li Y, Ding Z, Wu C. Mechanistic Study of the Inhibitory Effect of Kaempferol on Uterine Fibroids In Vitro. Medical Science Monitor. 2016;22:4803-4808. https://doi.org/10.12659/MSM.898127
Islam MS, Segars JH, Castellucci M, Ciarmela P. Dietary phytochemicals for possible preventive and therapeutic option of uterine fibroids: Signaling pathways as target. Pharmacological Reports. 2017;69:1:57-70. https://doi.org/10.1016/j.pharep.2016.10.013
Vieth R. The pharmacology of vitamin D. Vitamin D. 2011;1041-1066. https://doi.org/10.1016/B978-0-12-381978-9.10057-5
Mal’tsev SV, Rylova NV. Vitamin D and immunity. Prakticheskaya meditsina. 2015;1:86:114-120. (In Russ.)
Sabry M, Halder S, Ait Allah A, Roshdy E, Rajaratnam V, Al-Hendy. Serum vitamin D₃ level inversely correlates with uterine fibroid volume in different ethnic groups: A cross-sectional observational study. Int J Womens Health. 2013;5:1:93-100. https://doi.org/10.2147/IJWH.S38800
Baird DD, Hill MC, Schectman JM, nHollis BW. Vitamin D and the risk of uterine fibroids. Epidemiology. 2013;24:3:447-453. https://doi.org/10.1097/EDE.0b013e31828acca0
Paffoni A, Somigliana E, Vigano P, Benaglia L, Cardellicchio L, Pagliardini L, Papaleo E, Candiani M, Fedele L. Vitamin D status in women with uterine leiomyomas. J Clin Endocrinol Metab. 2013; 98:8:E1374-1378. https://doi.org/10.1210/jc.2013-1777
Ciebiera M, Wlodorczyk M, Slabuszewska-Jozwiak A, Nowicka G, Jakiel G. Original article: Influence of vitamin D and transforming growth factor β3 serum concentrations, obesity, and family history on the risk for uterine fibroids. Fertil Steril. 2016;3:1787-1792. https://doi.org/10.1016/j.fertnstert.2016.09.007
Wise LA, Ruiz-Narvaez EA, Haddad SA, Rosenberg L, Palmer JR. Polymorphisms in vitamin D-related genes and risk of uterine leiomyomata. Fertil Steril. 2014;102:2:503-510. https://doi.org/10.1016/j.fertnstert.2014.04.037
Blauer M, Rovio PH, Ylikomi T, Heinonen PK. Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro. Fertil Steril. 2009;91:5:1919-1925. https://doi.org/10.1016/j.fertnstert.2008.02.136
Halder SK, Goodwin JS, Al-Hendy A. 1,25-Dihydroxyvitamin D₃ reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2011;96:4: E754-E762. https://doi.org/10.1210/jc.2010-2131
Halder SK, Osteen KG, Al-Hendy A. 1,25-Dihydroxyvitamin D₃ Reduces Extracellular Matrix-Associated Protein Expression in Human Uterine Fibroid Cells. Biol Reprod. 2013;89:6:150.
Halder SK, Osteen KG, Al-Hendy A. Vitamin D₃ inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod. 2013;28:9:2407-2416. https://doi.org/10.1093/humrep/det265
Sharan C, Halder SK, Thota C, Jaleel T, Nair S, Al-Handy A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril. 2011;95:1:247-253. https://doi.org/10.1016/j.fertnstert.2010.07.1041
Al-Hendy A, Diamond MP, El-Sohemy A, Halder SK. 1,25-dihydroxyvitamin D₃ regulates expression of sex steroid receptors in human uterine fibroid cells. J Clin Endocrinol Metab. 2015;100:4:E572-E582. https://doi.org/10.1210/jc.2014-4011
Al-Hendy A. Vitamin D₃ Inhibits Wnt/β-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells. J Clin Endocrinol Metab. 2016;101:4:1542-1551. https://doi.org/10.1210/jc.2015-3555
Halder SK, Sharan C, Al-Hendy A. 1,25-dihydroxyvitamin D₃treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod. 2012;86:4:116:1-10. https://doi.org/10.1095/biolreprod.111.098145
Halder SK, Sharan C, Al-Hendy O, Al-Hendy A. Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine fibroids. Reprod Sci. 2014;21:9:1108-1119. https://doi.org/10.1177/1933719114537721
Savel'ev SV, Buyanova SN, Babunashvili EL, Mgeliashvili MV. Determination of the role of type IV collagen in the pathogenesis of uterine fibroids. Rossiiskii vestnik akushera-ginekologa. 2005;4:7-10. (In Russ.)
Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable Collagenase clostridium histolyticum: A new nonsurgical treatment for Dupuytren’s disease. Journal of Hand Surgery Am. 2010;35:12:2027-2038. https://doi.org/10.1016/j.jhsa.2010.08.007
Thomas A, Bayat A. The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease. Ther Clin Risk Manag. 2010;6:557-572. https://doi.org/10.2147/TCRM.S8591
Gelbard M, Goldstein I, Hellstorm WJ, McMahon CG, Smith T, Tursi J, Jones N, Kaufman GJ, Carson C.C. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:1:199-207. https://doi.org/10.1016/j.juro.2013.01.087
Warwick D, Arandes-Renu JM, Pajardi G, Witthaut J, Hurst LC. Collagenase clostridium histolyticum: Emerging practice patterns and treatment advances. J Plast Surg Hand Surg. 2016;50:5:251-261. https://doi.org/10.3109/2000656X.2016.1159568
Brunengraber L, Jayes F, Leppert P. Injectable Clostridium histolyticum collagenase as a potential treatment for uterine fibroids. Reprod Sci. 2014;21:12:1452-1459. https://doi.org/10.1177/1933719114553449
Pines M, Vlodavsky I, Nagler A. Halofuginone: From veterinary use to human therapy. Drug Dev Res. 2000;50:3-4:371-378.
Nagler A, Miao H-O, Aingorn H, Pines M, Genina O, Vlodavsky I. Inhibition of collagen synthesis, smooth muscle gell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arter Thromb Vasc Biol. 1997;17:1:194-508.
McGaha TL, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts. J Invest Dermatol. 2002;118:3:461-470. https://doi.org/10.1046/j.0022-202x.2001.01690.x
Nagler A, Firman N, Feferman R, Cotev S, Pines M, Shoshan S. Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med. 1996;154:4:1082-1086. https://doi.org/10.1164/ajrccm.154.4.8887611
Xavier S, Piek E, Fujii M, Javelaud D, Flanders KC, Samuni AM, Reiss M, Yarkoni S, Sowers A, Mitchell JB, Roberts AB, Russo A. Amelioration of radiation-induced fibrosis. Inhibition of transforming growth factor-β signaling by halofuginone. J Biol Chem. 2004; 279:15:15167-15176. https://doi.org/10.1074/jbc.M309798200
Grudzien MM, Low PS, Manning PC, Arredondo M, Belton RJ, Novak RA. The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells. Fertil Steril. 2010;93:4:1290-1298. https://doi.org/10.1016/j.fertnstert.2008.11.018
Taylor DK, Holthouser K, Segars JH, Leppert PC. Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management. F1000. Research. 2015;4: F1000 Faculty Rev: 183. https://doi.org/10.12688/f1000research.6189.1
Wright JC, Sekar M, Osdol WV, Su HC, Miksztal R. In book: Long acting injections and implants. Eds. Wright JC, Burgess DJ. New York: Springer. 2012;153-166. https://doi.org/10.1007/978-1-4614-0554-2
Ali H, Kilic G, Vincent K, Motamedi M, Rytting E. Nanomedicine for uterine leiomyoma therapy. Ther Deliv. 2013;4:2:161-175. https://doi.org/10.4155/tde.12.144

Close metadata